OrthoTrophix Reports TPX-100 Data in Knee Osteoarthritis
Foster City, California, United States, November 9, 2026 OrthoTrophix, Inc. has announced new clinical research findings from two scientific...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Foster City, California, United States, November 9, 2026 OrthoTrophix, Inc. has announced new clinical research findings from two scientific...
Foster City, California | April 24, 2026 OrthoTrophix has unveiled compelling new clinical findings highlighting the structural relationship between...
Lille & Paris, France — February 10, 2026: 4Moving Biotech (4MB), a clinical-stage biotechnology company and spin-off of 4P-Pharma,...
